Finance

Beta
Lists
3KY:FRA
Hansoh Pharmaceutical Group Company Ltd
€3.38
+1.17%
(+0.039) 1D
Jun 3, 12:40:09 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 3KY...
Open
€3.28
High
€3.38
Low
€3.28
Mkt. cap
183.51B
Avg. vol.
35.00
Volume
80.00
52-wk high
€4.80
52-wk low
€2.90
No. of employees
9K
Open
€3.28
High
€3.38
Low
€3.28
Mkt. cap
183.51B
Avg. vol.
35.00
Volume
80.00
52-wk high
€4.80
52-wk low
€2.90
No. of employees
9K
News stories
From sources across the web
Profile
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company that manufactures and sells various types of medicine in mainland China. It was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan, who is the company's chair. Zhong and her family own 66% of the company. It is the largest psychotropic drug producer in China. Hansoh Pharmaceutical had an initial public offering on the main board of the Hong Kong Stock Exchange on 14 June 2019. In August 2022, it was announced that the company's stock would be added to the Hang Seng Index. Wikipedia
About Hansoh Pharmaceutical Group Company Ltd
CEO-
Employees9.35K
Founded1995
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
3.72B
3.72B
3.80B
3.80B
Cost of goods sold
338.74M
338.74M
420.88M
420.88M
Cost of revenue
338.74M
338.74M
420.88M
420.88M
Research and development expenses
720.42M
720.42M
958.57M
958.57M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.08B
1.08B
1.29B
1.29B
Operating expense
1.80B
1.80B
2.25B
2.25B
Total operating expenses
2.14B
2.14B
2.67B
2.67B
Operating income
1.58B
1.58B
1.12B
1.12B
Other non operating income
24.43M
24.43M
31.11M
31.11M
EBT including unusual items
1.84B
1.84B
1.43B
1.43B
EBT excluding unusual items
1.86B
1.86B
1.42B
1.42B
Income tax expense
276.61M
276.61M
220.95M
220.95M
Effective tax rate
15.00%
15.00%
15.44%
15.44%
Other operating expenses
502.00K
502.00K
6.65M
6.65M
Net income
1.57B
1.57B
1.21B
1.21B
Net profit margin
42.17%
42.17%
31.87%
31.87%
Earnings per share
-
-
-
-
Interest and investment income
264.78M
264.78M
284.14M
284.14M
Interest expense
-816.50K
-816.50K
-764.50K
-764.50K
Net interest expenses
263.96M
263.96M
283.37M
283.37M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.67B
1.67B
1.21B
1.21B
Gain or loss from assets sale
-454.00K
-454.00K
-1.70M
-1.70M
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more